12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selumetinib: Phase II data

Data from 9 evaluable patients with advanced colorectal cancer refractory to standard therapy in an open-label, U.S. Phase II trial showed that once-daily 75 mg selumetinib plus once-weekly 90 mg MK-2206, an AKT inhibitor from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.),...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >